436 Rue Pierre et Marie Curie
About AntabioAntabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: (i) a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and (ii) a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval by 2021. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. The Company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies.
Founder and CEO: Marc Lemonnier
CSO: Martin Everett
Please click here for Antabio job opportunities.
Please click here for clinical trial information.
Tweets by Antabio
4 articles with Antabio
New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017
Antabio SAS announced today it has extended its Series A financing round with an additional €5.2 million subscribed by investment funds Omnes, BNP Paribas Développement, and Sham Innovation Santé.
Antabio is pleased to announce the addition of four highly successful and accomplished biotech executives to the management team.
ANTABIO Raises 7.3M Euros Series A Financing To Develop Novel Treatments Against Drug-Resistant Gram-Negative Infections
Antabio SAS announced today the completion of a 7.3M Euros series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.
Antabio Awarded Up To $8.9M From CARB-X To Accelerate The Development Of Its New Treatment For Chronic Infections In Cystic Fibrosis Patients